Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 3:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 155 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Primary Open-Angle Glaucoma (POAG) Clear all
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

NCT00868894
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
DE-104 medium concentration, DE-104 high concentration, Placebo, 0.005% latanoprost
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Artesia, California • Pasadena, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2011 · Synced Sep 30, 2026, 3:04 AM EDT
Completed No phase listed Observational Results available

Open Label Extension of LipoLat-CS202

NCT02599688
View directory record Official record
Conditions
Glaucoma
Interventions
Observation only
Other
Lead sponsor
Peregrine Ophthalmic
Industry
Eligibility
18 Years to 99 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Goose Creek, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 14, 2020 · Synced Sep 30, 2026, 3:04 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Comparing Preoperative Injection of Mitomycin-C vs. Intraoperative Injection of Mitomycin-C vs. Topical Application of Mitomycin-C (Conventional Use) in Trabeculectomy

NCT03875911
View directory record Official record
Conditions
Glaucoma Open-Angle Primary, Glaucoma, Open Angle Glaucoma, Glaucoma, Open-Angle
Interventions
Mitomycin C
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
20 Years to 85 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
4
States / cities
Arcadia, California • Fountain Valley, California • Los Angeles, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Sep 30, 2026, 3:04 AM EDT
Completed Not applicable Interventional Results available

Comparing Effectiveness of the Hydrus Microstent (TM) to Two iStents to Lower IOP in Phakic Eyes

NCT02023242
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Pseudoexfoliative Glaucoma, Pigmentary Glaucoma
Interventions
Hydrus Microstent, iStent Trabecular Micro Bypass
Device
Lead sponsor
Ivantis, Inc.
Industry
Eligibility
45 Years to 84 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Sep 30, 2026, 3:04 AM EDT
Completed Phase 2 Interventional Results available

An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert

NCT02537015
View directory record Official record
Conditions
Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost
Drug
Lead sponsor
ForSight Vision5, Inc.
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Fayetteville, Arkansas • Artesia, California • Newport Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Sep 30, 2026, 3:04 AM EDT
Completed Phase 2 Interventional

Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

NCT01868126
View directory record Official record
Conditions
Open-angle Glaucoma or Ocular Hypertension
Interventions
DE-117 ophthalmic solution, latanoprost ophthalmic solution, Placebo
Drug · Other
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
7
States / cities
Newport Beach, California • Morrow, Georgia • Kansas City, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Sep 30, 2026, 3:04 AM EDT
Completed Phase 1 Interventional Results available

Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma

NCT03131167
View directory record Official record
Conditions
Primary Open-angle Glaucoma (POAG), Ocular Hypertension
Interventions
SHP639 (n=60), Placebo Comparator (n=24)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 90 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 30, 2026, 3:04 AM EDT
Not listed Not applicable Interventional

Multicenter Post-Approval Study Of The Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery

NCT01841450
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
iStent, Cataract surgery
Device · Procedure
Lead sponsor
Glaukos Corporation
Industry
Eligibility
22 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
14
States / cities
Irvine, California • Montebello, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Sep 30, 2026, 3:04 AM EDT
Terminated Not applicable Interventional

Safety and Effectiveness of the Hydrus Microstent

NCT05198297
View directory record Official record
Conditions
Open Angle Glaucoma, Primary Open Angle Glaucoma, Pseudoexfoliation Glaucoma, Pigmentary Glaucoma
Interventions
Hydrus Microstent, Ophthalmic surgery
Device · Procedure
Lead sponsor
Alcon Research
Industry
Eligibility
45 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Bentonville, Arkansas • Zephyrhills, Florida • Fraser, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Sep 30, 2026, 3:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

H-1337 Ophthalmic Solution Phase 1/2

NCT03452033
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
H-1337 Placebo, H-1337 [1], H-1337 [2], H-1337 [3]
Drug
Lead sponsor
Allysta Pharmaceutical
Industry
Eligibility
18 Years to 99 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Goose Creek, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Sep 30, 2026, 3:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-Label Study of Safety of H1337 in Healthy Volunteers

NCT06572397
View directory record Official record
Conditions
Glaucoma Open-Angle Primary, Ocular Hypertension
Interventions
H-1337 1.0%
Drug
Lead sponsor
D. Western Therapeutics Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Sep 30, 2026, 3:04 AM EDT
Completed Phase 1 Interventional

Tolerability, Safety and Efficacy of RKI983 Eye Drops in Subjects With Primary Open Angle Glaucoma and Ocular Hypertension

NCT00515424
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
RKI983
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Timeline
Started 2007
U.S. locations
5
States / cities
Artesia, California • Rochester, New York • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Sep 30, 2026, 3:04 AM EDT
Not yet recruiting Not applicable Interventional

Comparison of Goniotomy Device Outcomes in Combined Phacoemulsification-goniotomy Surgeries

NCT07418853
View directory record Official record
Conditions
Open Angle Glaucoma (OAG), Primary Open Angle Glaucoma (POAG), Secondary Open Angle Glaucoma
Interventions
Goniotomy
Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 30, 2026, 3:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt

NCT03896633
View directory record Official record
Conditions
Glaucoma, Open Angle or Ocular Hypertension
Interventions
brinzolamide 1% ophthalmic suspension, Azopt 1%
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Sep 30, 2026, 3:04 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

NCT02059278
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
T-2345, Xalatan
Drug
Lead sponsor
Nephron Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Sep 30, 2026, 3:04 AM EDT
Not yet recruiting Phase 4 Interventional

Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)

NCT07048886
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Rocklatan (netarsudil 0.02% and latanoprost 0.005%), Systane
Drug
Lead sponsor
Center for Sight Las Vegas
Other
Eligibility
40 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Sep 30, 2026, 3:04 AM EDT
Completed Phase 2 Interventional

A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

NCT01917383
View directory record Official record
Conditions
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions
Trabodenoson, Latanoprost, Timolol
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Bristol, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Sep 30, 2026, 3:04 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Caffeine Consumption in Glaucoma Patients and Healthy Subjects

NCT03675412
View directory record Official record
Conditions
Glaucoma, Primary Open Angle
Interventions
Caffeine tablet
Dietary Supplement
Lead sponsor
Wills Eye
Other
Eligibility
18 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 30, 2026, 3:04 AM EDT
Completed No phase listed Observational

Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Postmarket Registry

NCT01841437
View directory record Official record
Conditions
Primary Open-angle Glaucoma
Interventions
iStent
Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
Not listed
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
18
States / cities
Chico, California • Huntington Beach, California • Napa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Sep 30, 2026, 3:04 AM EDT
Active, not recruiting Phase 4 Interventional

Use of Methazolamide to Lower Intraocular Pressure

NCT05498103
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
Methazolamide 25 MG, Methazolamide 50 MG
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Sep 30, 2026, 3:04 AM EDT
Terminated Phase 4 Interventional

A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma

NCT06407973
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
OMNI Surgical System, Latanoprost plus adjunctive glaucoma medication
Device · Drug
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
45 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Petaluma, California • Maryville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Sep 30, 2026, 3:04 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Punctum Plug Delivery System in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT00650702
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Latanoprost-PPDS
Drug
Lead sponsor
Mati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Artesia, California • Sacramento, California • Bel Air, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Sep 30, 2026, 3:04 AM EDT
Recruiting No phase listed Observational

DSLT Performance in Treatment-naïve Patients With Newly Diagnosed Open Angle Glaucoma

NCT06933836
View directory record Official record
Conditions
Open Angle Glaucoma (OAG)
Interventions
DSLT enables newly diagnosed patients to remain well controlled and off medications
Device
Lead sponsor
Barnet Dulaney Perkins Eye Centers
Network
Eligibility
30 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Sep 30, 2026, 3:04 AM EDT
Completed Phase 2 Interventional Results available

Study of LL-BMT1 in Patients With Elevated Intraocular Pressure

NCT04747808
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
LL-BMT1
Drug
Lead sponsor
MediPrint Ophthalmics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Sep 30, 2026, 3:04 AM EDT